Intranasal Oxytocin for ObesityFranziska Plessow, Elizabeth A. Lawson, Liya Kerem et al.|NEJM Evidence|2024Cited by 20
A randomized, double-blind, placebo-controlled clinical trial of 8-week intranasal oxytocin administration in adults with obesity: Rationale, study design, and methodsMarie‐Louis Wronski, Elizabeth A. Lawson, Franziska Plessow et al.|Contemporary Clinical Trials|2022Cited by 13
Arginine-Vasopressin Dynamics in Relation to Food Intake and 8-Week Intranasal Oxytocin Treatment in Adults With ObesityAnna Aulinas, Elizabeth A. Lawson, Francesca Galbiati et al.|The Journal of Clinical Endocrinology & Metabolism|2025Cited by 2
FRI004 Sex Differences In Oxytocin And Arginine-Vasopressin Levels Around A Standardized Meal In Adults With ObesityMarie‐Louis Wronski, Elizabeth A. Lawson, James T Sanislow et al.|Journal of the Endocrine Society|2023Cited by 0
Corrigendum to “A randomized, double-blind, placebo-controlled clinical trial of 8-week intranasal oxytocin administration in adults with obesity: Rationale, study design, and methods” [Contemporary Clinical Trials 122 (2022) 1-11/106909]Marie‐Louis Wronski, Elizabeth A. Lawson, Franziska Plessow et al.|Contemporary Clinical Trials|2024Cited by 0